ADA 2021: A Promising Future for Tirzepatide
Jul 17, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Jasmine Dumontier-Hiott, PharmD Candidate 2022, University of South Florida Taneja College of Pharmacy
American Diabetes Association symposium presents new phase 3 clinical trials of SURPASS-3 and SURPASS-5.
Tirzepatide is a once-weekly injectable medication for patients with type 2 diabetes who may not have achieved optimal therapeutic outcomes while taking oral antihyperglycemic medications. The novel dual GIP-GLP-1 agonist tirzepatide has demonstrated remarkable findings in the SURPASS-1 and SURPASS-2 phase 3 clinical trials. The SURPASS-1 trial of tirzepatide versus placebo concluded a significant HbA1C reduction below 5.7% in 31-52% of participants in the tirzepatide groups. The SURPASS-2 trial of tirzepatide versus semaglutide as an add-on to metformin established a substantial HbA1C reduction below 5.7% was achieved by 29-51% of the tirzepatide participants. Additional phase 3 trials further investigated whether the significant improvements in glycemic control continue compared to guideline-recommended treatments.
The SURPASS-3 is a randomized, open-label trial comparing the effect of tirzepatide versus titrated insulin degludec on glycemic control in patients with type 2 diabetes as an add-on to metformin....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.